Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | BCL9 | O00512 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11795322 | 0.85 | MAPT (0.52) | MAPTLMNAKDM4ECRHBPCRHR2 | |
| SCHEMBL8849171 | 0.85 | MMP8 (0.43) | LMNAALDH1A1SMN1; SMN2NPC1KMT2A | |
| SCHEMBL521125 | 0.84 | SLC6A3 (0.50) | MAPTLMNAKDM4EALDH1A1GAA | |
| SCHEMBL4279296 | 0.84 | MAPT (0.57) | MAPTLMNAKDM4ECRHBPCRHR2 | |
| SCHEMBL10771702 | 0.84 | MAPT (0.57) | MAPTLMNAKDM4ECRHBPCRHR2 | |
| SCHEMBL4053767 | 0.83 | MAPT (0.56) | MAPTLMNAKDM4ECRHBPCRHR2 | |
| SCHEMBL4136472 | 0.83 | ALDH1A1 (0.58) | MAPTLMNAKDM4ECRHBPCRHR2 | |
| SCHEMBL9308387 | 0.82 | LMNA (0.54) | MAPTLMNAKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL10479619 | 0.81 | MAPT (0.46) | MAPTLMNAKDM4ECRHBPCRHR2 | |
| SCHEMBL10479623 | 0.81 | MAPT (0.46) | MAPTLMNAKDM4ECRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| WO-2024126777-A1 | HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20220313826-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| CN-110511213-B | Immunomodulator | 成都先导药物开发股份有限公司 | 2021-10-19 | — | — | CN | disclosed |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| CN-110511213-A | A kind of immunomodulator | CHENGDU HITGEN DEV CO LTD | 2019-11-29 | — | — | CN | disclosed |
| EP-3455218-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20050069522-A1 | Combination pharmaceutical agents as inhibitors of HCV replication | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-31 | — | — | US | disclosed |
| WO-2004014852-A2 | IMINOTHIAZOLIDINONES AS INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014313-A2 | COMBINATION PHARMACEUTICAL AGENTS AS INHIBITORS OF HCV REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-0673400-A1 | POLYCYCLIC DYES | BASF AKTIENGESELLSCHAFT (DE) | 1995-09-27 | — | — | EP | disclosed |
| EP-0623120-A1 | PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1994-11-09 | — | — | EP | disclosed |
| WO-1994012577-A2 | POLYCYCLIC DYES | ZENECA LIMITED (GB) | 1994-06-09 | — | — | WO | disclosed |
| WO-1993014077-A1 | PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
| EP-0045165-B1 | RHODANINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION, AND ALDOSE REDUCTASE INHIBITORS CONTAINING SUCH DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1986-03-12 | — | — | EP | disclosed |
| US-4446143-A | Rhodanine derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-05-01 | — | — | US | disclosed |
| EP-0045165-A1 | Rhodanine derivatives, a process for their preparation, and aldose reductase inhibitors containing such derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | MAPT 4032/4885LMNA 2573/4885KDM4E 1603/4885 |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | MAPT 2494/4885LMNA 2919/4885KDM4E 1634/4885 |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | MAPT 2494/4885LMNA 2919/4885KDM4E 1634/4885 |
| US-20050069522-A1 | Combination pharmaceutical agents as inhibitors of HCV replication | IMPDH1, IMPDH2, IMPA1 | MAPT 4776/4885LMNA 4429/4885KDM4E 3512/4885 |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | MAPT 2494/4885LMNA 2919/4885KDM4E 1634/4885 |
| US-20220313826-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | MAPT 2494/4885LMNA 2919/4885KDM4E 1634/4885 |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | MAPT 2494/4885LMNA 2919/4885KDM4E 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.